Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Alpha Teknova
TKNO
Alpha Teknova
Funding Gaps Will Hamper Biopharma Yet Resilience Will Emerge
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
10 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$8.00
44.0% undervalued
intrinsic discount
16 Aug
US$4.48
Loading
1Y
-11.3%
7D
1.6%
Author's Valuation
US$8.0
44.0% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$8.0
44.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-52m
58m
2019
2021
2023
2025
2027
2028
Revenue US$58.0m
Earnings US$7.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.00%
Life Sciences revenue growth rate
0.32%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.36%
Calculation
US$7.42m
Earnings '28
x
72.02x
PE Ratio '28
=
US$534.50m
Market Cap '28
US$534.50m
Market Cap '28
/
54.16m
No. shares '28
=
US$9.87
Share Price '28
US$9.87
Share Price '28
Discounted to 2025 @ 7.35% p.a.
=
US$7.98
Fair Value '25
